Efficacy and Safety of Potent Oral P2Y12 Inhibitors in Medically Managed ACS Patients: a Meta-analysis

Li, Zhiguo; Yu, Peng; Song, Hee-Jung; Jiang, Zaixin; Li, Yi; Han, Yaling

doi:10.1007/s10557-020-06940-y

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(13,14) In the PLATO trial, compared with clopidogrel, treatment with ticagrelor signi cantly reduced the rate of death from vascular causes, MI, or stroke in patients with ACS (7). Several studies comparing the long-term bene ts and MACEs associated with ticagrelor versus clopidogrel (15)(16)(17)(18)(19) have reported signi cant reductions in the risk of MACEs following the administration of ticagrelor with aspirin. However, few studies have focused on the loading of DAPT in the ED for patients with AMI before PCI.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Prognosis Between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Huang

Shih

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Dual antiplatelet therapy (DAPT) is a standard treatment option for acute myocardial infarction (AMI). The difference between the efficacy of ticagrelor and clopidogrel in the emergency department (ED) before percutaneous coronary intervention (PCI) remains unknown. The present study compared the in-hospital major adverse cardiovascular event (MACE) rates between patients with AMI treated with clopidogrel and those treated with ticagrelor in the ED before PCI. Methods We retrospectively collected the data of patients diagnosed as having AMI in the ED. Patients were only included if they had successfully received complete DAPT with aspirin and ticagrelor/clopidogrel in the ED and had undergone PCI. The patients were divided into 2 groups according to their DAPT regimen. The primary outcome was the rate of in-hospital MACEs. The secondary outcomes included an unexpected return to the ED within 72 h, readmission within 14 d, and revascularization. Results 1836 patients were enrolled. Patients in the ticagrelor group had a lower in-hospital MACE rate (3.01% versus 7.51%, P < .001) and in-hospital mortality rate (2.15% versus 5.70%, P < .001) than those in the clopidogrel group. Multivariate logistic regression analysis revealed ticagrelor was independently associated with a lower risk of in-hospital MACEs (odds ratio [OR]: 0.53, 95% CI: 0.32–0.88, P = .013). By conditional logistic regression with a propensity score matching, similar results were found (OR 0.41, 95% CI: 0.18–0.91, P = .028) Conclusion DAPT with ticagrelor and aspirin in the ED before PCI is associated with a lower in-hospital MACE rate among patients with AMI.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Prognosis Between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Huang

Shih

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In the PLATO trial, compared with clopidogrel, treatment with ticagrelor significantly reduced the rate of death from vascular causes, MI, or stroke in patients with ACS [ 7 ]. Several studies comparing the long-term benefits and MACEs associated with ticagrelor versus clopidogrel [ 15 , 16 , 17 , 18 , 19 ] have reported significant reductions in the risk of MACEs following the administration of ticagrelor with aspirin. However, few studies have focused on the loading of DAPT in the ED for patients with AMI before PCI.…”

Section: Discussionmentioning

confidence: 99%

Comparison of In-Hospital Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Treated with Ticagrelor or Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

Background: Dual antiplatelet therapy (DAPT) is a standard treatment option for acute myocardial infarction (AMI). The difference between the efficacy of ticagrelor and clopidogrel in the emergency department (ED) before percutaneous coronary intervention (PCI) remains unknown. The present study compared the in-hospital major adverse cardiovascular event (MACE) rates between patients with AMI treated with clopidogrel and those treated with ticagrelor in the ED before PCI. Methods: We retrospectively collected the data of patients diagnosed as having AMI in the ED. Patients were only included if they had successfully received complete DAPT with aspirin and ticagrelor/clopidogrel in the ED and had undergone PCI. The patients were divided into two groups according to their DAPT regimen. The primary outcome was the rate of in-hospital MACEs. The secondary outcomes included an unexpected return to the ED within 72 h, readmission within 14 d, and revascularization. Results: A total of 1836 patients were enrolled. Patients in the ticagrelor group had a lower in-hospital MACE rate (3.01% versus 7.51%, p < 0.001) and in-hospital mortality rate (2.15% versus 5.70%, p < 0.001) than those in the clopidogrel group. Multivariate logistic regression analysis revealed ticagrelor was independently associated with a lower risk of in-hospital MACEs (odds ratio [OR]: 0.53, 95% CI: 0.32–0.88, p = 0.013). After propensity score matching, the risk of in-hospital MACEs remained significantly lower in the ticagrelor group (OR 0.42, 95% CI: 0.21–0.85, p = 0.016). Conclusion: DAPT with ticagrelor and aspirin in the ED before PCI is associated with a lower in-hospital MACE rate among patients with AMI.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Prognosis between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Efficacy and Safety of Potent Oral P2Y12 Inhibitors in Medically Managed ACS Patients: a Meta-analysis

Cited by 3 publications

References 29 publications

Comparison of Prognosis Between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Comparison of Prognosis Between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Comparison of In-Hospital Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Treated with Ticagrelor or Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Comparison of Prognosis between Patients with Acute Myocardial Infarction Treated with Ticagrelor and Clopidogrel in the Emergency Department: A Propensity Score Matched Retrospective Cohort Study

Contact Info

Product

Resources

About